Iga nephropathy
Drug research and approvals for iga nephropathy: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 69 studies of iga nephropathy are recruiting on ClinicalTrials.gov, Health Canada has authorized 15 drug trials for it since 2013, and FDA has 0 approved and 2 open orphan designations naming it.
- Recruiting worldwide: 69
- Trials authorized in Canada: 15
- FDA orphan approvals: 0
- EU medicines: 0
- Pediatric Longitudinal Glomerular Disease: a PNRC Multi-Institutional Cohort StudyNCT07931170 · Not reported · Pediatric Nephrology Research Consortium · starts Oct 1, 2026
- A Phase 3 Blinded Study of JADE101 in Participants With Immunoglobulin A NephropathyNCT07902817 · Phase 3 · Jade Biosciences, Inc. · starts Dec 1, 2026
- A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab…NCT07890909 · Phase 3 · Vertex Pharmaceuticals Incorporated · starts Nov 13, 2026
- A Study of the Efficacy and Safety of Zigakibart + Atrasentan in Adult Patients With Primary IgA NephropathyNCT07850752 · Phase 3 · Novartis Pharmaceuticals · starts Nov 11, 2026
- To Assess the Efficacy and Safety of Utilizing Galactose-deficient IgA1 Biomarker Changes to Guide Pathogenic…NCT07822100 · Not applicable · Hong Zhang · starts Aug 24, 2026
- A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgANNCT07773727 · Phase 2 · argenx · starts Nov 5, 2026
- A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA NephropathyNCT07616700 · Phase 2 · Haisco Pharmaceutical Group Co., Ltd. · starts Aug 25, 2025
- Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of EVER001 in Participants With Selected…NCT07614477 · Phase 2 · Everest Medicines (China) Co.,Ltd. · starts May 20, 2026
- Safety and Efficacy of STL303 In Patients With Primary Immunoglobulin A (IgA) NephropathyNCT07606352 · Phase 2 · Sitala Bio LTD · starts Aug 4, 2026
How its trials ended
184 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 41 whose ending is known, 41% met their primary endpoint, 7% missed it and 51% stopped early.
- Ongoing6636%
- Completed, result not reported4927%
- Status unknown2815%
- Met its primary endpoint179%
- Stopped: other or unclear84%
- Stopped: sponsor or business decision74%
- Stopped: enrollment or feasibility42%
- Missed its primary endpoint32%
- Stopped: lack of efficacy21%
| Aug 18, 2026 | A phase 2, multicenter, randomized, placebo-controlled study to evaluate the efficacy, safety, and tolerability of ARGX-121 sc in adult participants with…ARGX-121 | argenx US | Pending |
| Jan 21, 2026 | A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary iga nephropathyZigakibart (FUB523) | Novartis Pharmaceuticals | Ongoing |
| Oct 31, 2025 | A phase 3 multicenter, randomized, double-blind, placebo controlled trial to evaluate efficacy and safety of mezagitamab (TAK-079) in study participants with…Mezagitamab (TAK-079) | Takeda Pharmaceuticals USA | Ongoing |
| Dec 13, 2024 | A phase 3, randomized, double-blind, placebo-controlled study of felzartamab in adults with iga nephropathyFelzartamab | Biogen | Ongoing |
| Jul 24, 2023 | A phase III, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sefaxersen, an antisense inhibitor of…Sefaxersen (RO7434656) | Roche | Ongoing |
| Jul 11, 2023 | A phase 3, randomized, double-blind, placebo-controlled study of BION-1301 in adults with iga nephropathy (the beyond study)BION-1301 (zigakibart) | Chinook Therapeutics | Ongoing |
| Feb 11, 2022 | A phase IIb randomized, double-blinded, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of atacicept in subjects with iga…Atacicept | Vera Therapeutics | Ongoing |
| Oct 15, 2021 | A multicenter rollover extension program (REP) to evaluate the long-term safety and tolerability of open label iptacopan in adult participants with primary iga…Iptacopan (LNP023) | Novartis Pharmaceuticals | Closed |
| May 28, 2021 | A double blind, randomized, placebo-controlled, multicenter phase IIa, clinical trial to assess efficacy and safety of the human ANTI-CD38 antibody felzartamab…Felzartamab (MOR202) | Human Immunology Biosciences, Inc. (Hi-Bio) | Ongoing |
| Mar 1, 2021 | A phase 3, randomized, double-blind, placebo-controlled study of atrasentan in patients with iga nephropathy at risk of progressive loss of renal function (the…Atrasentan / Zigakibart (FUB523) | Chinook Therapeutics U.S. | Ongoing |
| Nov 2, 2004 | Human monoclonal antibody against platelet-derived growth…To slow the progression of IgA nephropathy and delay kidney failure in patients affected by the disease. | CuraGen Corporation | Designated |
| May 4, 2000 | Omega-3 (n-3) polyunsaturated fatty acidsTreatment of IgA nephropathy. | Pronova Biocare, AS | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA